Home/Vir Biotechnology/Jeff Calcagno
JC

Jeff Calcagno

Executive Vice President and Chief Business Officer

Vir Biotechnology

Vir Biotechnology Pipeline

DrugIndicationPhase
VIR-2218 + VIR-3434 (Combination)Chronic Hepatitis Delta (HDV)Phase 3
PRO-XTEN® Platform CandidatesUndisclosed Oncology IndicationsPre-clinical